Human hepatocytes produce an isoform of Fas that inhibits apoptosis

Transplantation

Volumn 65, Issue 5, 1998, Pages 713-721

  Krams, Sheri M ^a   Fox, Christine K ^a   Beatty, P Robert ^a   Cao, Sean ^a   Villanueva, Janeth C ^a   Esquivel, Carlos O ^a   Martinez, Olivia M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FAS ANTIGEN; RNA; TUMOR NECROSIS FACTOR RECEPTOR;

ALLOGRAFT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LIVER CELL; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD95; APOPTOSIS; BILE; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; GRAFT REJECTION; HUMANS; LIVER; LIVER TRANSPLANTATION; LYMPHOCYTES; RNA, MESSENGER; SOLUBILITY; TRANSCRIPTION, GENETIC;

EID: 0032521061     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199803150-00019     Document Type: Article

References (44)

1. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445.
2. Benedetti A, Jezaquel M, Orlandi F. Preferential distribution of apoptotic bodies in acinar zone 3 of normal human and rat liver. J Hepatol 1988; 7: 319.
3. Patel T, Gores G. Apoptosis and hepatobiliary disease. Hepatology 1995; 21: 1725.
4. Krams S, Egawa H, Quinn M, Villanueva J, Garcia-Kennedy R, Martinez O. Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation 1995; 59: 621.
5. Galle P, Hofmann W, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223.
6. Ando K, Guidotti L, Wirth S, et al. Class I-restricted T lymphocytes are directly cytopathic for their targets in vivo. J Immunol 1994; 152: 3245.
7. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449.
8. Watanabe-Fukunaga R, Brannan C, Itoh M, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274.
9. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effects of the anti-Fas antibody in mice. Nature 1993; 364: 806.
10. Dong C, Wilson J, Winters G, McManus B. Human transplant coronary artery disease:pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest 1996; 74: 921.
11. Larsen C, Alexander D, Hendrix R, Ritchie S, Pearson T. Fasmediated cytotoxicity: an immunoeffector or immunoregulatory pathway in T cell-mediated immune responses. Transplantation 1995; 60: 221.
12. Sharma VK, Bologa RM, Li B, et al. Molecular executors of cell death-differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 1996; 62: 1860.
13. Krams SM, Martinez OM. Apoptosis as a mechanism of tissue injury in liver allograft rejection. Semin Liver Dis (in press).
14. 13a. Krams SM, Hayashi M, Fox CK, et al. CD8+ cells are not necessary for allograft rejection nor the induction of apoptosis in an experimental model of small intestine transplantation. J Immunol (in press).
15. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630.
16. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109.
17. Yagita H, Seino K, Kayagaki N, Okumura K. CD95 ligand in graft rejection. Nature 1996; 379: 682.
18. Kang S-M, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738.
19. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgeneic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
20. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706.
21. Cheng J, Zhou T, Liu C, et al. Protection from fas-mediated apoptosis by a soluble form of fas molecule. Science 1994; 263: 1759.
22. Hughes D, Crispe I. A naturally occurring soluble isoform of murine Fas is generated by alternative splicing. J Exp Med 1995; 182: 1395.
23. Knipping E, Krammer P, Onel K, Lehman T, Mysler E, Elkon K. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rhematoid arthritis. Arthritis Rheum 1995; 12: 1735.
24. Natoli G, Ianni A, Costanzo A, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995; 11: 1157.
25. Knipping E, Debatin K-M, Sticker K, Heilig B, Eder A, Krammer P. Identification of soluble APO-1 in supernatants of human B and T cell lines and increased serum levels in B and T cell leukemias. Blood 1995; 85: 1562.
26. Martinez O, Villanueva J, Gershwin M, Krams S. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology 1995; 21: 113.
27. Krams S, Villanueva J, Quinn M, Martinez O. Expression of the cytotoxic T cell mediator granzyme B during liver allograft rejection. Transplant Immunol 1995; 3: 162.
28. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991.; 66: 233.
29. Afford S, Hubscher S, Strain A, Adams D, Neuberger J. Apoptosis in the human liver during allograft rejection and end-stage liver disease. J Pathol 1995; 176: 373.
30. Ito H, Kasagi N, Shomori K, Osaki M, Adachi H. Apoptosis in the human allografted kidney: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling. Transplantation 1995; 60: 794.
31. Lang T, Krams S, Martinez O. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized organ grafts. Transplantation 1996; 62: 776.
32. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995; 11: 294.
33. Hiramatsu N, Hayashi N, Katayama K, et al. Immumohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 1354.
34. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential role of the Fas ligand in the development of hepatitis. Nature Medicine 1997; 3: 409.
35. Farges O, Morris P, Dallman M. Spontaneous acceptance of liver allografts in the rat: analysis of the immune response. Transplantation 1994; 57: 171.
36. Kamada N, Davies H, Roser B. Reversal of transplantation immunity by liver grafting. Nature 1981; 292: 840.
37. Sumimoto R, Kamada N. Specific suppression of allograft rejection by soluble class I antigen and complexes with monoclonal antibody. Transplantation 1990; 50: 678.
38. Goel N, Ulrich D, St. Clair E, Fleming J, Lynch D, Seldin M. Lack of correlation between serum and soluble fas/apo-1 levels and autoimmune disease. Arthritis Rheum 1995; 38: 1738.
39. Midis G, Shen Y, Owen-Schaub L. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996; 56: 3870.
40. Papoff G, Cascino I, Erama A, Starace G, Lynch D, Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622.
41. Liu C, Cheng J, Mountz J Differential expression of human fas mRNA species upon peripheral blood mononuclear cell activation. Biochem J 1995; 310: 957.
42. Sato T, Irie S, Kitada S, Reed J FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411.
43. Lacronique V, Mignon A, Fabre M, et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 1996; 2: 80.
44. Rodriguez I, Matsuura K, Khatib K, Reed J, Nagata S, Vassalli P. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 1996; 183: 1031.